CRISIL reaffirms AA+ rating; bank loan limit raised to Rs 1,100 cr

New Credit FacilityCredit & Debt View source PDF

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-0.2%1-day move

₹830.00

prior close

₹829.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-1.5-2.0-2.0-2.3-0.2+0.6+0.1-1.4-1.7+0.0-3.0———

Up moveDown movePending

AI summary

CRISIL reaffirmed Alembic Pharmaceuticals credit ratings: AA+/Stable on bank loan facilities (Rs 1,100 cr, enhanced from Rs 800 cr) and A1+ on commercial paper (Rs 1,100 cr). The enhanced bank loan limit signals increased working capital access spread across eight banks including HDFC, RBL, SBI, Kotak, HSBC, Citibank, and Axis Bank.

Likely market impact

Strong high-grade credit profile retained; higher bank borrowing capacity supports working capital and growth needs.